Rpg Life Sciences Limited (RPGLIFE)
ISIN: INE105J01010 Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
511.65
11.7(2.34%)

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in the area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, oncology, urology, respiratory, vitamins and minerals, gastro intestinal, pain management, cardio-vascular, etc. primarily under the Lomotil, Lomofen+, Naprosyn, Azoran, Aldactone, and Serenace brand names. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

Pricing Updates

TODAY'S HIGH

515.7

TODAY'S LOW

504

52 WEEK HIGH

752.45

52 WEEK LOW

424.85

Major Holders

% of Shares Held by
All Insider

69.84%

% of Shares Held by
Institutions

5.11%

% of Float Held by
Institutions

16.96%

Number of Institutions
Holding Shares

2

Company Overview

MARKET CAP

846.21 Cr.

ETERPRISE VALUE

906.87 Cr.

NO. OF SHARES

1.65 Cr.

BOOK VALUE

141.325

DIV. YIELD

None%

DEBT

94 Lakhs

GROSS PROFIT

301.33 Cr.

CASH

70.26 Cr.

REVENUE

443.14 Cr.

REVENUE/SHARE

267.973

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-11.97 Cr.-11.97 Cr.-11.97 Cr.-11.97 Cr.
Change To Liabilities-1.91 Cr.3.12 Cr.19.33 Cr.-26.73 Cr.
Total cashflows from Investing Activities-34.66 Cr.-7.96 Cr.-10.70 Cr.-19.02 Cr.
Net Borrowings-1.08 Cr.-9.70 Cr.-24.81 Cr.-17.72 Cr.
Total Cash from Financing Activities-13.51 Cr.-10.49 Cr.-39.30 Cr.-26.50 Cr.
Other Liabilities-1.35 Cr.-1.15 Cr.7.40 Cr.-15 Lakhs
Total Assets0000
Net Income51.48 Cr.40 Cr.29.01 Cr.10.81 Cr.
Change in Cash16.58 Cr.39.82 Cr.17 Lakhs26 Lakhs
Effect of Exchange Rate0000
Total Cash from Operating Activities64.75 Cr.58.27 Cr.50.17 Cr.45.78 Cr.
Depreciation15.66 Cr.15.73 Cr.15.57 Cr.14.57 Cr.
Other Cashflows from Investing Activities1.26 Cr.50 Lakhs50 Lakhs55 Lakhs
Dividends Paid-11.91 Cr.-11.91 Cr.-10.59 Cr.-3.97 Cr.
Change to Inventory-24.66 Cr.-11.72 Cr.-5.57 Cr.12.65 Cr.
Change to Account Receivables24.81 Cr.6.22 Cr.-23.53 Cr.28.60 Cr.
Other Cashflows from Financing Activities-52 Lakhs-79 Lakhs-3.90 Cr.-4.81 Cr.
Change to Net Income72 Lakhs5.33 Cr.7.17 Cr.5.28 Cr.
Capital Expenditures-23.95 Cr.-8.51 Cr.-10.74 Cr.-19.68 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax73.17 Cr.53.58 Cr.36.45 Cr.15.05 Cr.
Minority InterestNoneNoneNoneNone
Net Income73.69 Cr.53.66 Cr.42.95 Cr.18.69 Cr.
Selling General Administrative99.97 Cr.102.75 Cr.99.27 Cr.98.81 Cr.
Gross Profit301.33 Cr.253.54 Cr.243.62 Cr.216.17 Cr.
Ebit73.69 Cr.53.66 Cr.42.95 Cr.18.69 Cr.
Operating Income73.69 Cr.53.66 Cr.42.95 Cr.18.69 Cr.
Other Operating Expenses112.01 Cr.80.66 Cr.85.04 Cr.83.74 Cr.
Interest Expense-52 Lakhs-79 Lakhs-1.75 Cr.-3.99 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense21.69 Cr.13.58 Cr.7.44 Cr.4.24 Cr.
Total Revenue443.15 Cr.389.14 Cr.375.57 Cr.330.16 Cr.
Total Operating Expenses369.46 Cr.335.48 Cr.332.62 Cr.311.47 Cr.
Cost of Revenue141.82 Cr.135.60 Cr.131.95 Cr.113.99 Cr.
Total Other Income Expense Net-52 Lakhs-8 Lakhs-6.50 Cr.-3.64 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.51.48 Cr.40 Cr.29.01 Cr.10.81 Cr.
Net Income Applicable to Common Shares51.48 Cr.40 Cr.29.01 Cr.10.81 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets34.68 Cr.37.13 Cr.41.87 Cr.52.18 Cr.
Capital Surplus034.46 Cr.34.46 Cr.34.46 Cr.
Total Liabilities88.84 Cr.86.94 Cr.90.16 Cr.90.74 Cr.
Stock Holder Equity255.77 Cr.216.45 Cr.176.57 Cr.160.50 Cr.
Minority Interest0000
Other Liabilities33.97 Cr.17.79 Cr.15.35 Cr.14.39 Cr.
Total Assets344.61 Cr.303.39 Cr.266.73 Cr.251.24 Cr.
Common Stock13.23 Cr.13.23 Cr.13.23 Cr.13.23 Cr.
Retained Earnings0168.71 Cr.128.83 Cr.112.76 Cr.
Other Liabilities8.43 Cr.6.51 Cr.6.05 Cr.6.34 Cr.
Good Will0000
Treasury Stock242.54 Cr.5 Lakhs5 Lakhs5 Lakhs
Other Assets2.93 Cr.2.47 Cr.8.08 Cr.9.34 Cr.
Cash70.26 Cr.40.36 Cr.54 Lakhs37 Lakhs
Current Liabilities80.11 Cr.79.69 Cr.82.59 Cr.77.82 Cr.
Long Term Asset Charges06 Lakhs4.60 Cr.6.18 Cr.
Short Long Term Debt28 Lakhs11 Lakhs4.44 Cr.20 Lakhs
Other Stockholder Equity242.54 Cr.5 Lakhs5 Lakhs5 Lakhs
Property Plant Equipment100.09 Cr.87.94 Cr.91 Cr.92.63 Cr.
Total Cur. Assets206.91 Cr.175.85 Cr.125.78 Cr.97.09 Cr.
Long Term Investments0000
Net Tangible Assets221.09 Cr.179.32 Cr.134.70 Cr.108.32 Cr.
Short Term Investments0000
Net Receivables33.01 Cr.61.85 Cr.66.92 Cr.42.38 Cr.
Long Term Debt1 Lakh8 Lakhs22 Lakhs4.63 Cr.
Inventory82.99 Cr.58.33 Cr.46.61 Cr.41.04 Cr.
Accounts Payable45.50 Cr.47.44 Cr.44.41 Cr.25.13 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account